Your browser is no longer supported. Please, upgrade your browser.
Jazz Pharmaceuticals plc
Index- P/E53.32 EPS (ttm)3.16 Insider Own3.00% Shs Outstand55.55M Perf Week1.71%
Market Cap9.29B Forward P/E9.98 EPS next Y16.90 Insider Trans-3.79% Shs Float54.14M Perf Month12.34%
Income179.20M PEG9.11 EPS next Q4.23 Inst Own- Short Float6.39% Perf Quarter16.00%
Sales2.28B P/S4.07 EPS this Y24.50% Inst Trans-0.01% Short Ratio6.58 Perf Half Y49.23%
Book/sh60.80 P/B2.77 EPS next Y33.86% ROA3.10% Target Price181.74 Perf Year13.11%
Cash/sh34.80 P/C4.85 EPS next 5Y5.85% ROE5.80% 52W Range86.88 - 171.69 Perf YTD2.18%
Dividend- P/FCF11.86 EPS past 5Y57.70% ROI12.80% 52W High-1.77% Beta1.07
Dividend %- Quick Ratio3.80 Sales past 5Y13.00% Gross Margin94.10% 52W Low94.12% ATR4.31
Employees1620 Current Ratio4.00 Sales Q/Q11.80% Oper. Margin11.40% RSI (14)67.69 Volatility2.39% 2.68%
OptionableYes Debt/Eq0.62 EPS Q/Q48.00% Profit Margin7.90% Rel Volume0.72 Prev Close165.77
ShortableYes LT Debt/Eq0.55 EarningsNov 02 AMC Payout0.00% Avg Volume526.04K Price168.65
Recom1.80 SMA203.94% SMA5010.28% SMA20028.91% Volume378,395 Change1.74%
Dec-16-20Initiated UBS Buy $174
Nov-03-20Reiterated H.C. Wainwright Buy $185 → $195
Oct-09-20Reiterated H.C. Wainwright Buy $175 → $185
Sep-14-20Resumed JP Morgan Overweight $175
Sep-14-20Downgrade Goldman Neutral → Sell $128
Aug-06-20Upgrade Morgan Stanley Equal-Weight → Overweight $177
Jul-28-20Upgrade Wolfe Research Peer Perform → Outperform
Jul-23-20Upgrade H.C. Wainwright Neutral → Buy
Apr-06-20Initiated Jefferies Buy $149
Mar-12-20Upgrade Bernstein Mkt Perform → Outperform $166
Jan-08-20Initiated Goldman Neutral $153
Aug-21-19Downgrade Piper Jaffray Overweight → Neutral $205 → $142
Jun-11-19Initiated Barclays Overweight $164
Mar-20-19Initiated SunTrust Buy $163
Dec-14-18Initiated Wolfe Research Peer Perform
Nov-08-18Reiterated B. Riley FBR Buy $219 → $190
Aug-08-18Reiterated Stifel Buy $180 → $205
Jul-11-18Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-23-18Reiterated H.C. Wainwright Neutral $150 → $160
Mar-19-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-14-21 12:34PM  
Jan-10-21 03:59AM  
Jan-04-21 04:05PM  
Dec-22-20 10:27AM  
Dec-21-20 08:00AM  
Dec-04-20 08:44AM  
Dec-03-20 02:00AM  
Dec-02-20 11:30AM  
Nov-20-20 09:40AM  
Nov-17-20 07:30AM  
Nov-10-20 04:05PM  
Nov-09-20 12:34PM  
Nov-05-20 07:30AM  
Nov-04-20 08:32AM  
Nov-03-20 11:55AM  
Nov-02-20 06:35PM  
Oct-30-20 11:03AM  
Oct-26-20 12:31PM  
Oct-20-20 07:30AM  
Oct-19-20 04:15PM  
Oct-18-20 06:36AM  
Oct-14-20 04:05PM  
Oct-10-20 03:00PM  
Oct-09-20 12:42PM  
Oct-08-20 04:18PM  
Oct-07-20 07:21AM  
Oct-05-20 11:40AM  
Oct-02-20 11:08AM  
Sep-24-20 02:52PM  
Sep-23-20 06:10AM  
Sep-17-20 11:40AM  
Sep-15-20 08:00AM  
Sep-14-20 10:01AM  
Sep-09-20 07:30AM  
Sep-08-20 04:05PM  
Sep-04-20 06:02PM  
Sep-03-20 11:31AM  
Sep-01-20 12:20PM  
Aug-27-20 08:36AM  
Aug-21-20 12:24PM  
Aug-05-20 12:10PM  
Aug-04-20 06:45PM  
Aug-03-20 12:12PM  
Jul-30-20 07:32PM  
Jul-28-20 12:33PM  
Jul-22-20 01:49PM  
Jul-21-20 04:05PM  
Jul-13-20 08:00AM  
Jul-12-20 12:53PM  
Jun-30-20 09:31AM  
Jun-18-20 02:19PM  
Jun-16-20 10:15AM  
Jun-15-20 03:35PM  
Jun-09-20 09:26AM  
Jun-08-20 07:00AM  
Jun-04-20 11:31AM  
May-30-20 06:01PM  
May-27-20 04:05PM  
May-14-20 09:53AM  
May-13-20 02:57PM  
May-11-20 08:30AM  
May-09-20 08:10AM  
May-08-20 01:11AM  
May-06-20 11:39AM  
May-05-20 06:45PM  
May-04-20 10:57AM  
May-03-20 07:36AM  
Apr-29-20 04:05PM  
Apr-28-20 12:33PM  
Apr-21-20 04:05PM  
Apr-17-20 02:16PM  
Apr-13-20 10:29AM  
Apr-07-20 06:40AM  
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE CChairman & CEOJan 04Sale162.017,9501,287,980319,532Jan 06 04:35 PM
Carr PatriciaVP, Finance & PAODec 04Sale152.55629,4586,200Dec 08 05:09 PM
COZADD BRUCE CChairman & CEODec 03Sale150.0025037,500327,482Dec 03 04:26 PM
COZADD BRUCE CChairman & CEODec 01Sale140.581,000140,580327,732Dec 03 04:26 PM
ENRIGHT PATRICK GDirectorNov 12Sale146.729,9291,456,73820,368Nov 13 04:56 PM
Larkin FinbarSVP, Technical OperationsNov 06Sale151.9319729,93013,964Nov 10 06:16 PM
O'Keefe Kenneth WDirectorNov 05Sale154.8611,0001,703,42118,667Nov 09 04:53 PM
Sohn Catherine A.DirectorNov 04Option Exercise59.4012,500742,56018,622Nov 06 04:42 PM
BERNS PAUL LDirectorNov 04Sale150.424,691705,6049,740Nov 04 07:33 PM
Sohn Catherine A.DirectorNov 04Sale153.4412,5001,918,00010,622Nov 06 04:42 PM
COZADD BRUCE CChairman & CEONov 03Sale154.002,500385,000328,680Nov 04 07:24 PM
COZADD BRUCE CChairman & CEONov 02Sale145.131,000145,130331,180Nov 04 07:24 PM
COZADD BRUCE CChairman & CEOOct 01Sale141.944,500638,730332,180Oct 05 07:21 PM
Larkin FinbarSVP, Technical OperationsSep 09Sale138.53638,72714,161Sep 10 06:48 PM
COZADD BRUCE CChairman & CEOSep 01Sale134.9050067,450336,680Sep 03 04:49 PM
COZADD BRUCE CChairman & CEOAug 27Sale130.003,000390,000337,180Aug 31 05:45 PM
Carr PatriciaVP, Finance & PAOAug 12Sale123.8014217,5806,200Aug 14 05:33 PM
Carr PatriciaVP, Finance & PAOAug 07Sale125.8715819,8876,342Aug 11 07:51 PM
Winningham Rick EDirectorAug 07Sale125.87931117,1856,198Aug 10 04:57 PM
Sohn Catherine A.DirectorAug 07Sale125.87931117,18610,622Aug 10 04:54 PM
RIEDEL NORBERT GDirectorAug 07Sale125.87931117,1869,459Aug 10 04:50 PM
O'Keefe Kenneth WDirectorAug 07Sale125.87931117,1867,418Aug 10 04:48 PM
McSharry Heather AnnDirectorAug 07Sale125.871,009127,00310,333Aug 10 04:45 PM
BERNS PAUL LDirectorAug 07Sale125.87931117,1859,740Aug 10 04:40 PM
Carr PatriciaVP, Finance & PAOJun 05Sale124.0013817,1126,500Jun 05 04:47 PM
Mulligan SeamusDirectorMay 27Buy111.2635,0003,894,0581,152,788May 27 06:36 PM
Mulligan SeamusDirectorMay 26Buy110.6515,0001,659,7471,117,788May 27 06:36 PM
Carr PatriciaVP, Finance & PAOMar 12Sale102.1760061,3026,500Mar 13 06:48 PM
MILLER MICHAEL PATRICKEVP, US CommercialMar 12Sale102.171,500153,25522,118Mar 13 06:46 PM
Larkin FinbarSVP, Technical OperationsMar 09Sale111.4961568,56613,883Mar 10 06:06 PM
Carr PatriciaVP, Finance & PAOMar 09Sale111.4556863,3037,100Mar 10 06:05 PM
Larkin FinbarSVP, Technical OperationsMar 06Sale119.1529234,79314,498Mar 10 06:06 PM
Carr PatriciaVP, Finance & PAOMar 06Sale119.1723227,6487,668Mar 10 06:05 PM
Carr PatriciaVP, Finance & PAOMar 04Sale118.6725330,0247,900Mar 05 07:42 PM
Larkin FinbarSVP, Technical OperationsMar 03Sale119.7527933,41014,790Mar 05 07:44 PM
Carr PatriciaVP, Finance & PAOMar 03Sale119.7524729,5788,153Mar 05 07:42 PM
COZADD BRUCE CChairman & CEOFeb 24Option Exercise11.486,89579,155305,783Feb 26 05:12 PM
MILLER MICHAEL PATRICKEVP, US CommercialFeb 13Sale142.181,500213,27026,571Feb 14 05:39 PM
COZADD BRUCE CChairman & CEOFeb 03Sale143.831,000143,830298,888Feb 05 04:28 PM